APA

G Estevez L., Fortes J. L., Adrover E., Peiró G., Margel M., Castellá E., Cuevas J. M., Bernet L., Segui M. A. & Andreu X. (20090430). Doxorubicin and cyclophosphamide followed by weekly docetaxel as neoadjuvant treatment of early breast cancer: analysis of biological markers in a GEICAM phase II study. : Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico.

Chicago

G Estevez L, Fortes J L, Adrover E, Peiró G, Margel M, Castellá E, Cuevas J M, Bernet L, Segui M A and Andreu X. 20090430. Doxorubicin and cyclophosphamide followed by weekly docetaxel as neoadjuvant treatment of early breast cancer: analysis of biological markers in a GEICAM phase II study. : Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico.

Harvard

G Estevez L., Fortes J. L., Adrover E., Peiró G., Margel M., Castellá E., Cuevas J. M., Bernet L., Segui M. A. and Andreu X. (20090430). Doxorubicin and cyclophosphamide followed by weekly docetaxel as neoadjuvant treatment of early breast cancer: analysis of biological markers in a GEICAM phase II study. : Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico.

MLA

G Estevez L, Fortes J L, Adrover E, Peiró G, Margel M, Castellá E, Cuevas J M, Bernet L, Segui M A and Andreu X. Doxorubicin and cyclophosphamide followed by weekly docetaxel as neoadjuvant treatment of early breast cancer: analysis of biological markers in a GEICAM phase II study. : Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico. 20090430.